Biotechnology

BioInvent International AB: Year-End Report January 1 - December 31, 2024

February 27, 2025 2:30 AM

BioInvent International (STO:BINV) "2024 was a year with several exciting developments reported from across our broad portfolio of clinical programs. We now have two Phase 2 and four Phase 1 trials running in our six clinical programs leveraging the TNFR2 and FcyRIIB targets. Throughout the year, we pursued building our business by expanding our management team and signing important clinical collaboration and supply agreements with key...

Read more

Vicore Pharma Holding Year-End Report 2024

February 27, 2025 2:30 AM

Vicore Pharma Holding (STO:VICO) Stockholm, February 27, 2025 - Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today published the year-end report for 2024. "The fourth quarter was another pivotal period for Vicore as the company successfully raised over SEK 880 million (USD ~85 million) in financing transactions, while ramping up the global,...

Read more

FluoGuide A/S Publishes Year-End and Annual Report for the Fiscal Year 2024

February 27, 2025 1:20 AM

FluoGuide A/S (STO:FLUO) Copenhagen, Denmark, 27 February 2025 - FluoGuide A/S ("FluoGuide" or the "Company") hereby publishes its annual report for the fiscal year 2024. The annual report, including the auditor's report, is attached as a PDF and is also available on FluoGuide's website www.fluoguide.com under ‘Filings & Reports'. FINANCIAL HIGHLIGHTS KEY FIGURES 2024 2023 2022 2021 2020 DKK thousand Income Statement Income before...

Read more

FluoGuide A/S Publishes Interim Report for the Period January - December 2024

February 27, 2025 1:20 AM

FluoGuide A/S (STO:FLUO) Copenhagen, Denmark, 27 February 2025 - Fluoguide A/S ("FluoGuide" or the "Company") today releases its results for the period 1 January 2024 - 31 December 2024. The Q4 report is available as attached document to this press release and on FluoGuide's website. In the fourth quarter, the Company submitted a clinical trial application for the FG001 phase II head and neck trial application (CT-005). This milestone reflects...

Read more

Natural Dior LLC Issues Voluntary Nationwide Recall of Vitafer-L Gold Liquid Due to Presence of Undeclared Tadalafil

February 26, 2025 5:00 PM

Natural Dior LLC, is voluntarily recalling the affected lots of Vitafer-L Gold Liquid, a dietary supplement with iron and vitamins, to the consumer level. The product has been found to contain undeclared tadalafil, an ingredient in FDA approved products for treatment of male erectile dysfunction in the family of drugs known as phosphodiesterase (PDE-5) inhibitors. Products containing tadalafil cannot be marketed as dietary supplements. Vitafer-L...

Read more

ClearPoint Neuro Reports Fourth Quarter and Full Year 2024 Results

February 26, 2025 4:05 PM

ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its fourth quarter and full-year ended December 31, 2024. 2024 Full Year and Fourth Quarter Highlights Reported fourth quarter 2024 revenue of $7.8 million, a 14% year-over-year increase compared with the fourth quarter of 2023; Reported revenue of...

Read more

BRK Technology Outlines Growth Strategy for 2025 as SAF Interest Intensifies

February 26, 2025 9:00 AM

As global demand for sustainable aviation fuel (SAF) accelerates, BRK Technology Co., Limited, a leader in next-generation algae-based biofuels, today unveiled its strategic roadmap for 2025. With governments, airlines, and industry stakeholders prioritizing decarbonization, the company is expanding production capacity, advancing research into high-yield algae strains, and strengthening strategic partnerships to accelerate the commercialization...

Read more

Alligator Bioscience Announces Continued Encouraging Overall Survival Benefit for Mitazalimab

February 26, 2025 3:20 AM

Alligator Bioscience (STO:ATORX) Alligator Bioscience (Nasdaq Stockholm:ATORX) today reports updated results from the Phase 2 OPTIMIZE-1 study evaluating mitazalimab in combination with standard chemotherapy (mFOLFIRINOX) as a first-line treatment for metastatic pancreatic cancer. The 24-month analysis of the 900 µg/kg dose reconfirms and extends the significant survival benefit and reinforces the potential of mitazalimab as a breakthrough...

Read more

Vicore to Present at Upcoming Investor Conferences

February 26, 2025 2:20 AM

Vicore Pharma Holding (STO:VICO) Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following investor conferences: TD Cowen 45th Annual Health Care Conference Location: Boston, USA Format: Presentation and 1x1 meetings Presentation Date and Time: Tuesday, March 4 at 11:50 AM ET/5:50 PM CET Webcast:...

Read more

Notice of Extraordinary General Meeting in Alligator Bioscience AB

February 25, 2025 11:45 AM

Alligator Bioscience (STO:ATORX) The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201, are invited to the extraordinary general meeting to be held on Thursday 27 March 2025 at 14.00 CET, at Medicon Village, conference room Bengt, Scheelevägen 4 in Lund, Sweden. RIGHT TO...

Read more

The Board of Directors of Alligator Bioscience Propose a Reverse Share Split of Ordinary Shares

February 25, 2025 11:30 AM

The Board of Directors of Alligator Bioscience AB (STO:ATORX)("Alligator Bioscience" or the "Company") proposes that an Extraordinary General Meeting on 27 March 2025 resolves to carry out a reverse share split of ordinary shares, in the ratio 1:1,000, resulting in one thousand (1,000) ordinary shares being consolidated into one (1) ordinary share (the "Reverse Share Split"). Notice of the Extraordinary General Meeting will be published through...

Read more

Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study

February 25, 2025 9:20 AM

Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, announces top-line results of its expanded Application Comprehension ("App Comp") study, which determines consumer comprehension of its unique messaging within its proprietary Technology. In the study, the Company's technology facilitated consumer's...

Read more

NOK Therapeutics, Inc. to Attend 10th Annual Innate Killer Summit in San Diego

February 25, 2025 9:00 AM

NOK Therapeutics, Inc., a biotech firm dedicated to developing novel immunotherapies leveraging NK cell biology and committed to delivering transformative treatments for cancer and other serious diseases, will be attending the 10th Annual Innate Killer Summit in San Diego in March, which unites long-standing senior pioneers in the NK space annually to focus on advancing the development of NK cell therapies, engagers and cytokine-based approaches...

Read more

Invitation to Presentation of BioInvent's Year-end Report 2024

February 25, 2025 8:25 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts, and the press to a presentation of the Year-end report 2024 on February 27 at 4:00 pm CET. The report will be published at 8:00 am CET the same day. BioInvent's CEO Martin Welschof will present the report together with CFO Stefan Ericsson. The presentation will be held in English. When: Thursday February 27, 2025, at 4:00 pm CET The webcast can be...

Read more

CB Scientific Inc. (CBSC) Formally Launches Next Generation MyCardia AT Cardiac Monitor

February 25, 2025 6:30 AM

CB Scientific, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company"), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products, announced today that the Company, in partnership with its contract manufacturer Datrix, LLC, is launching its next generation MyCardia AT cardiac event monitor targeted for use with our international distribution network in SE Asia, Hong Kong, and Macau. The newly branded MyCardia AT...

Read more

Alligator Bioscience's Rights Issue is Registered - Conversion of BTU into Shares and Warrants

February 24, 2025 1:45 PM

Alligator Bioscience (STO:ATORX) Alligator Bioscience AB ("Alligator Bioscience" or the "Company") has carried out a rights issue of units, consisting of ordinary shares, warrants series TO 12 and warrants series TO 13, where the subscription period ended on 12 February 2025 (the "Rights Issue"). The Rights Issue was registered with the Swedish Companies Registration Office today on 24 February 2025. The last day of trading in paid subscribed...

Read more

Sunset City Medicinal Mushrooms of Calgary: A Forward-Looking Trend for Mental Health

February 23, 2025 10:45 PM

In a context where health and wellness are at the forefront of public concern, Sunset City Medicinal Mushrooms positions itself as a key player in Calgary, offering innovative solutions through its medicinal mushroom products. With a strong commitment to the future of natural health, the brand aspires to transform how Calgarians approach their well-being. A Promise of Innovation Sunset City Medicinal Mushrooms (www.sunsetcity.ca) is dedicated to...

Read more

Andrew Young Champions the Adoption of Green Practices in Biotechnology

February 20, 2025 7:45 PM

Andrew Young, the CEO of Conjugate Group, is advocating for enhanced sustainability practices within the biotechnology industry. Young is urging biotech companies to integrate eco-friendly innovations and green technologies to minimize environmental impact and drive sustainable development. "Sustainability in biotech is not just an option; it's an obligation," said Andrew Young. "As leaders in an industry focused on improving human health, we...

Read more

Alligator Bioscience Carries Out a Directed Issue of Units to Guarantors and a Directed Issue of Warrants to Fenja Capital in Connection with the Completed Rights Issue

February 20, 2025 1:00 PM

Alligator Bioscience (STO:ATORX) The Board of Directors of Alligator Bioscience AB ("Alligator Bioscience" or the "Company"), has today, based on the authorization granted by the extraordinary general meeting on 13 January 2025, resolved on a directed issue of 84,560,000 units to guarantors who have entered into guarantee commitments in the rights issue of units announced on 2 December 2024 (the "Rights Issue") and who have chosen to receive...

Read more

Prolocor to Present New Clinical Evidence at ACC 25 Supporting Use of PLATELET FCɣRIIA (PFCG) As Key Tool In Individualizing Dual Antiplatelet Therapy (DAPT)

February 20, 2025 12:45 PM

Prolocor, Inc., a healthcare startup developing the innovative diagnostic Prolocor pFCG™ test that identifies patients at higher and lower risk of thrombotic events (heart attack, stroke, and death), announced today the acceptance of its abstract entitled PROGNOSTIC IMPLICATIONS OF PLATELET FCɣRIIA DURING THE FIRST YEAR AFTER MYOCARDIAL INFARCTION as a moderated poster presentation at The American College of Cardiology's 74th Annual Scientific...

Read more